Cargando…
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial
BACKGROUND: The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871018/ https://www.ncbi.nlm.nih.gov/pubmed/33563325 http://dx.doi.org/10.1186/s13063-021-05033-x |
_version_ | 1783648929448984576 |
---|---|
author | Gyselinck, Iwein Liesenborgs, Laurens Landeloos, Ewout Belmans, Ann Verbeke, Geert Verhamme, Peter Vos, Robin Janssens, W. |
author_facet | Gyselinck, Iwein Liesenborgs, Laurens Landeloos, Ewout Belmans, Ann Verbeke, Geert Verhamme, Peter Vos, Robin Janssens, W. |
author_sort | Gyselinck, Iwein |
collection | PubMed |
description | BACKGROUND: The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic, known for its immunomodulatory properties. It has shown antiviral effect specifically against SARS-CoV-2 in vitro and acts on cytokine signaling pathways that have been implicated in COVID-19. METHODS: DAWn-AZITHRO is a randomized, open-label, phase 2 proof-of-concept, multicenter clinical trial, evaluating the safety and efficacy of azithromycin for treating hospitalized patients with COVID-19. It is part of a series of trials testing promising interventions for COVID-19, running in parallel and grouped under the name DAWn-studies. Patients hospitalized on dedicated COVID wards are eligible for study inclusion when they are symptomatic (i.e., clinical or radiological signs) and have been diagnosed with COVID-19 within the last 72 h through PCR (nasopharyngeal swab or bronchoalveolar lavage) or chest CT scan showing typical features of COVID-19 and without alternate diagnosis. Patients are block-randomized (9 patients) with a 2:1 allocation to receive azithromycin plus standard of care versus standard of care alone. Standard of care is mostly supportive, but may comprise hydroxychloroquine, up to the treating physician’s discretion and depending on local policy and national health regulations. The treatment group receives azithromycin qd 500 mg during the first 5 consecutive days after inclusion. The trial will include 284 patients and recruits from 15 centers across Belgium. The primary outcome is time from admission (day 0) to life discharge or to sustained clinical improvement, defined as an improvement of two points on the WHO 7-category ordinal scale sustained for at least 3 days. DISCUSSION: The trial investigates the urgent and still unmet global need for drugs that may impact the disease course of COVID-19. It will either provide support or else justify the discouragement of the current widespread, uncontrolled use of azithromycin in patients with COVID-19. The analogous design of other parallel trials of the DAWN consortium will amplify the chance of identifying successful treatment strategies and allow comparison of treatment effects within an identical clinical context. TRIAL REGISTRATION: EU Clinical trials register EudraCT Nb 2020-001614-38. Registered on 22 April 2020 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05033-x. |
format | Online Article Text |
id | pubmed-7871018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78710182021-02-09 Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial Gyselinck, Iwein Liesenborgs, Laurens Landeloos, Ewout Belmans, Ann Verbeke, Geert Verhamme, Peter Vos, Robin Janssens, W. Trials Study Protocol BACKGROUND: The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic, known for its immunomodulatory properties. It has shown antiviral effect specifically against SARS-CoV-2 in vitro and acts on cytokine signaling pathways that have been implicated in COVID-19. METHODS: DAWn-AZITHRO is a randomized, open-label, phase 2 proof-of-concept, multicenter clinical trial, evaluating the safety and efficacy of azithromycin for treating hospitalized patients with COVID-19. It is part of a series of trials testing promising interventions for COVID-19, running in parallel and grouped under the name DAWn-studies. Patients hospitalized on dedicated COVID wards are eligible for study inclusion when they are symptomatic (i.e., clinical or radiological signs) and have been diagnosed with COVID-19 within the last 72 h through PCR (nasopharyngeal swab or bronchoalveolar lavage) or chest CT scan showing typical features of COVID-19 and without alternate diagnosis. Patients are block-randomized (9 patients) with a 2:1 allocation to receive azithromycin plus standard of care versus standard of care alone. Standard of care is mostly supportive, but may comprise hydroxychloroquine, up to the treating physician’s discretion and depending on local policy and national health regulations. The treatment group receives azithromycin qd 500 mg during the first 5 consecutive days after inclusion. The trial will include 284 patients and recruits from 15 centers across Belgium. The primary outcome is time from admission (day 0) to life discharge or to sustained clinical improvement, defined as an improvement of two points on the WHO 7-category ordinal scale sustained for at least 3 days. DISCUSSION: The trial investigates the urgent and still unmet global need for drugs that may impact the disease course of COVID-19. It will either provide support or else justify the discouragement of the current widespread, uncontrolled use of azithromycin in patients with COVID-19. The analogous design of other parallel trials of the DAWN consortium will amplify the chance of identifying successful treatment strategies and allow comparison of treatment effects within an identical clinical context. TRIAL REGISTRATION: EU Clinical trials register EudraCT Nb 2020-001614-38. Registered on 22 April 2020 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05033-x. BioMed Central 2021-02-09 /pmc/articles/PMC7871018/ /pubmed/33563325 http://dx.doi.org/10.1186/s13063-021-05033-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Gyselinck, Iwein Liesenborgs, Laurens Landeloos, Ewout Belmans, Ann Verbeke, Geert Verhamme, Peter Vos, Robin Janssens, W. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial |
title | Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial |
title_full | Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial |
title_fullStr | Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial |
title_full_unstemmed | Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial |
title_short | Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial |
title_sort | direct antivirals working against the novel coronavirus: azithromycin (dawn-azithro), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against sars-cov-2—azithromycin trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871018/ https://www.ncbi.nlm.nih.gov/pubmed/33563325 http://dx.doi.org/10.1186/s13063-021-05033-x |
work_keys_str_mv | AT gyselinckiwein directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial AT liesenborgslaurens directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial AT landeloosewout directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial AT belmansann directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial AT verbekegeert directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial AT verhammepeter directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial AT vosrobin directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial AT janssensw directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial AT directantiviralsworkingagainstthenovelcoronavirusazithromycindawnazithroarandomizedmulticenteropenlabeladaptiveproofofconceptclinicaltrialofnewantiviralsworkingagainstsarscov2azithromycintrial |